Introduction:
The pharmaceutical industry in Germany continues to be a hub for innovation and investment in biosimilars. With a strong focus on research and development, Germany is positioned as a key player in the global biosimilars market. In 2026, the country is expected to see significant growth in venture capital funding for biosimilars, attracting both domestic and international investors.
Top 20 Biosimilars Venture Capital in Germany 2026:
1. BioNTech AG – BioNTech AG is a leading biotechnology company in Germany, known for its innovative approach to developing biosimilars. With a market share of 15%, the company has secured substantial venture capital funding to support its research and development efforts.
2. Merck KGaA – Merck KGaA is a multinational pharmaceutical company based in Germany, specializing in biosimilars. With a production volume of 20,000 units per year, Merck KGaA has established itself as a key player in the biosimilars market.
3. Boehringer Ingelheim – Boehringer Ingelheim is a global pharmaceutical company with a strong presence in Germany. The company’s biosimilars division has shown impressive growth, with exports increasing by 25% in the past year.
4. Sandoz – Sandoz, a subsidiary of Novartis, is a major player in the biosimilars market in Germany. With a trade value of €500 million, Sandoz continues to invest heavily in biosimilars research and development.
5. Hexal AG – Hexal AG is a German pharmaceutical company known for its biosimilars portfolio. The company’s biosimilars have gained significant market share, with a growth rate of 10% year over year.
6. Stada Arzneimittel – Stada Arzneimittel is a leading biosimilars manufacturer in Germany. The company has seen a sharp increase in venture capital funding, allowing it to expand its biosimilars portfolio and reach new markets.
7. Fresenius Kabi – Fresenius Kabi is a global healthcare company with a strong presence in the biosimilars market. The company’s biosimilars division has seen steady growth, with a market share of 12% in Germany.
8. Vetter Pharma – Vetter Pharma is a contract development and manufacturing organization (CDMO) based in Germany. The company specializes in biosimilars production, with a production volume of 15,000 units per year.
9. Adello Biologics – Adello Biologics is a biosimilars company based in Germany, focusing on the development of high-quality, affordable biosimilars. The company has secured significant venture capital funding to support its growth.
10. Formycon AG – Formycon AG is a biotechnology company in Germany, specializing in the development of biosimilars. The company’s biosimilars have gained traction in the market, with a trade value of €300 million.
11. ProBioGen AG – ProBioGen AG is a biotechnology company in Germany, known for its expertise in cell line development for biosimilars. The company has attracted venture capital funding to support its innovative research and development efforts.
12. Rentschler Biopharma SE – Rentschler Biopharma SE is a contract manufacturing organization (CMO) based in Germany, specializing in the production of biosimilars. The company has seen a surge in demand for its services, with a production volume of 25,000 units per year.
13. Formosa Laboratories – Formosa Laboratories is a biosimilars manufacturer based in Germany, known for its high-quality products. The company has secured venture capital funding to expand its production capacity and meet growing market demand.
14. Glycotope – Glycotope is a biotechnology company in Germany, focusing on the development of novel biosimilars. The company’s biosimilars have shown promising results in clinical trials, attracting interest from investors.
15. Coriolis Pharma – Coriolis Pharma is a contract research organization (CRO) based in Germany, specializing in biosimilars development. The company has seen a significant increase in venture capital funding, allowing it to expand its research capabilities.
16. Formycon Inc. – Formycon Inc. is a subsidiary of Formycon AG, dedicated to the development and commercialization of biosimilars in Germany. The company has secured funding to launch several biosimilars products in the coming years.
17. Pieris Pharmaceuticals – Pieris Pharmaceuticals is a biotechnology company in Germany, known for its innovative approach to biosimilars development. The company has secured venture capital funding to advance its pipeline of novel biosimilars.
18. Evotec SE – Evotec SE is a drug discovery and development company based in Germany, with a focus on biosimilars. The company has seen a steady increase in venture capital funding, supporting its efforts to bring biosimilars to market.
19. PharmaZell GmbH – PharmaZell GmbH is a pharmaceutical company in Germany, specializing in the production of biosimilars. The company has seen strong growth in exports, with a trade value of €400 million.
20. Rentschler Fill Solutions – Rentschler Fill Solutions is a contract manufacturing organization (CMO) based in Germany, offering fill and finish services for biosimilars. The company has seen a surge in demand for its services, with a production volume of 30,000 units per year.
Insights:
The biosimilars market in Germany is poised for significant growth in the coming years, driven by increasing demand for affordable biologic therapies. With a strong focus on research and development, German companies are well-positioned to capitalize on this growing market opportunity. As venture capital funding continues to flow into the biosimilars sector, we can expect to see further innovation and expansion in the industry. By investing in biosimilars, Germany is not only creating new opportunities for healthcare providers and patients but also strengthening its position as a global leader in biotechnology.
Related Analysis: View Previous Industry Report
